Scope Fluidics

Scope Fluidics Rule of 40

The Rule of 40 of Scope Fluidics (SCP.WA) as of Nov 15, 2026 is -47,250.66 %. In the previous year, Rule of 40 was 58,745.23 % — a change of -180.43% (lower).

Rule of 40

-47,250.66 %

YoY

-180.43%

Last updated:

Rule of 40 of Scope Fluidics is 2025 -47,250.66 % . Rule of 40 of Scope Fluidics was 2024 58,745.23 % . It decreases by -180.43% lower compared to the previous year.

The Scope Fluidics Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2016
-2,021.55 PLN
Jan 1, 2017
-231,312.30 PLN
Jan 1, 2023
-5,531.00 PLN
Jan 1, 2024
58,745.23 PLN
Jan 1, 2025
-47,250.66 PLN
The Scope Fluidics Rule of 40 history
YEARRule of 40YoY
-47,250.66 %-180.43%
58,745.23 %-1,162.11%
-5,531.00 %-97.61%
-231,312.30 %+11,342.32%
-2,021.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Rule of 40 of Scope Fluidics is -47,250.66 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Scope Fluidics

All Key Metrics — Scope Fluidics